450-91-9

Usage

Uses

Used in Pharmaceutical Industry:
4-Fluoro-2-methoxyaniline is used as a synthetic intermediate for the preparation of ortho-substituted phenylureas, which are known as 5-Hydroxytryptamine (5-HT3) receptor antagonists. These antagonists play a crucial role in treating various conditions, such as nausea, vomiting, and migraines, by blocking the action of serotonin on the 5-HT3 receptors.
Additionally, 4-Fluoro-2-methoxyaniline is utilized in the synthesis of hydroxamic acids and their prodrugs. These compounds act as inhibitors for the Botulinum neurotoxin A light chain, which is a significant concern in the development of therapeutics against botulism, a severe and potentially fatal form of food poisoning.

Physical Form

Yellow to Orange to Brown Solid or liquid

InChI:InChI=1/C7H8FNO/c1-10-7-4-5(8)2-3-6(7)9/h2-4H,9H2,1H3

Upstream product

• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 446-36-6 5-fluoro-2-nitrophenol 
• 456-49-5 1-fluoro-3-methoxybenzene 
• 7440-02-0 nickel 
• 446-35-5 2,4-Difluoronitrobenzene 
• 82344-33-0 N-hydroxy-N-(2-methoxyphenyl)acetamide 
• 582-11-6 N-(4-fluoro-2-methoxyphenyl)acetamide 

Downstream Products

• 148624-87-7 4-fluoro-2-methoxyphenyl isocyanate 
• 102392-11-0 1-(4-fluoro-2-methoxyphenyl)piperazine 
• 582-11-6 N-(4-fluoro-2-methoxyphenyl)acetamide 
• 1075705-01-9 4-fluoro-2-methoxy-5-nitro-phenylamine 
• 1332761-22-4 4-(4-fluoro-2-methoxy-phenylamino)-5-methyl-thieno[2,3-d]pyrimidine-6-carboxylic acid methyl ester 
• 1453199-61-5 N-(2-methoxy-4-(4-methylpiperazin-1-yl)-5-nitrophenyl)-4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-amine 
• 1421372-35-1 6-methoxy-4-(4-methylpiperazin-1-yl)-N₁-(4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-yl)benzene-1,3-diamine 
• 1421373-53-6 N-(4-methoxy-2-(4-methylpiperazin-1-yl)-5-(4-(pyrazolo[1,5-a]pyridin-3-yl)pyrimidin-2-ylamino)phenyl)acrylamide 
• 1407520-45-9 N-(5-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-4-methoxy-2-(2-(4-methylpiperazin-1-yl)ethoxy)phenyl)acrylamide 
• 1551577-12-8 methyl 3-(2,4-dichlorophenyl)-5-((4-fluoro-2-methoxyphenyl)amino)-5-oxopentanoate 
• 1421373-82-1 C₂₇H₃₄N₈O₂ 
• 1421373-80-9 C₂₆H₃₄N₈O₂ 
• 1421373-78-5 C₂₇H₂₇N₉O₂ 

Relevant academic research and scientific papers

Industrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles-catalyzed hydrogenation of nitroarenes

The development of green and efficient methods for hydrogenation of nitroarenes is still highly demanding in organic synthesis. Herein, we report an industrial Cunninghamia lanceolata carbon supported FeO(OH) nanoparticles process for the synthesis of aryl amines with good yields via hydrogenation of nitroarenes. Nine key anti-cancer drug intermediates were successfully achieved with protocol. And Osimertinib intermediate 4m can be smoothly synthesized at a 2.67 kg-scale with >99.5% HPLC purity. This protocol features cheap carbon source, highly catalytic activity, simple operation, kilogram-scalable and recyclable catalysts (eight times without observable losing activity).

New inha inhibitors based on expanded triclosan and di-triclosan analogues to develop a new treatment for tuberculosis

The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) has reinforced the need for the development of new anti-TB drugs. The first line drug isoniazid inhibits InhA. This is a prodrug requiring activation by the enzyme KatG. Mutations in KatG have largely contributed to clinical isoniazid resistance. We aimed to design new ‘direct’ InhA inhibitors that obviate the need for activation by KatG, circumventing pre-existing resistance. In silico molecular modelling was used as part of a rational structure-based drug-design approach involving inspection of protein crystal structures of InhA:inhibitor complexes, including the broad spectrum antibiotic triclosan (TCS). One crystal structure exhibited the unusual presence of two triclosan molecules within the Mycobacterium tuberculosis InhA binding site. This became the basis of a strategy for the synthesis of novel inhibitors. A series of new, flexible ligands were designed and synthesised, expanding on the triclosan structure. Low Minimum Inhibitory Concentrations (MICs) were obtained for benzylphenyl compounds (12, 43 and 44) and di-triclosan derivative (39), against Mycobacterium bovis BCG although these may also be inhibiting other enzymes. The ether linked di-triclosan derivative (38) displayed excellent in vitro isolated enzyme inhibition results comparable with triclosan, but at a higher MIC (125 μg mL?1 ). These compounds offer good opportunities as leads for further optimisation.

Compound for inhibiting three-mutant epidermal growth factor receptor tyrosine kinase and application thereof

The invention discloses a compound for inhibiting three-mutant epidermal growth factor receptor tyrosine kinase, and is characterized in that the structural formula is as follows. Among them: Substituent R1 . One of: Substituent R2 . One of: The substituent X is H or Cl. Substituent R3 To H. One of the following.

4 - Fluorine substituted aryl amine compound and synthesis method thereof

The invention discloses a synthesis method of 4 -fluorine substituted aryl amine compound, which comprises the following steps: 1) taking acyl-protected phenylhydroxylamine as a substrate, and generating 4 -fluorine substituted aniline compound under basic conditions by taking sulfonyl fluoride as a fluorine source in a polar solvent. 2) The deprotection is carried out under dilute acid conditions or Pd by catalytic hydrogenation to give the 4 - fluorine-substituted aryl amine compound. 4 - Fluorine substituted aniline compounds which are synthesized by the invention greatly increase the lipophilic property due to the introduction of fluorine atoms, and can be widely applied to preparation of fluorine-containing drugs and pesticide and dye intermediates. , The adopted raw materials are industrial products, are cheap and easily available, and are commercially available. 4 - Fluoroaryl aniline prepared by the method is high in yield, and the product with the purity 90% can be obtained in a yield of more than ≥ 99%. The method is simple to operate and low in cost, is very suitable for industrialization, and can be widely popularized and used.

Development of Radiohalogenated Osimertinib Derivatives as Imaging Probes for Companion Diagnostics of Osimertinib

Osimertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor approved for treating non-small-cell lung cancer (NSCLC) with EGFR mutations. Genetic testing is required to detect the mutation for selecting patients who can use osimert

Novel crystal form of deuterated AZD9291 compound and application thereof (by machine translation)

The invention belongs to the technical field of medicines, and particularly discloses a preparation method AZD9291 of a novel crystal form, and of deuterated . and application AZD9291 of the deuterated, crystal form is stable in crystal form, crystal form stability compared with crystal form DVS by combining suspension experiment with acceleration stability study, at normal temperature and accelerated stability. AZD9291. The present invention further discloses the crystal form A of a deuterated C . crystal form. (by machine translation)

Benzothiazolyl ureas are low micromolar and uncompetitive inhibitors of 17Β-HSD10 with implications to Alzheimer’s disease treatment

Human 17β-hydroxysteroid dehydrogenase type 10 is a multifunctional protein involved in many enzymatic and structural processes within mitochondria. This enzyme was suggested to be involved in several neurological diseases, e.g., mental retardation, Parkinson’s disease, or Alzheimer’s disease, in which it was shown to interact with the amyloid-beta peptide. We prepared approximately 60 new compounds based on a benzothiazolyl scaffold and evaluated their inhibitory ability and mechanism of action. The most potent inhibitors contained 3-chloro and 4-hydroxy substitution on the phenyl ring moiety, a small substituent at position 6 on the benzothiazole moiety, and the two moieties were connected via a urea linker (4at, 4bb, and 4bg). These compounds exhibited IC50 values of 1–2 μM and showed an uncompetitive mechanism of action with respect to the substrate, acetoacetyl-CoA. These uncompetitive benzothiazolyl inhibitors of 17β-hydroxysteroid dehydrogenase type 10 are promising compounds for potential drugs for neurodegenerative diseases that warrant further research and development.

The therapeutic effect of the anticancer agent for predicting alternative (by machine translation)

[Problem] non-small cell lung cells resistant to various epidermal growth factor receptor gene mutation appears when, for selecting alternative anticancer effects, minimally invasive or non-invasive diagnosis of a genetic therapeutic effect of anticancer agent can be labeled with radioactive alternative predicted. The therapeutic effect of the anticancer agent is predicted [solution] alternatively, the anticancer drug is selected to be labeled with a radioactive isotope which alternate, the anticancer drug resistance should be selected to be an alternative to the anticancer agent is preferably labeled with a radioactive isotope as an alternative. The therapeutic effect of the anticancer agent is an alternative prediction, wherein the anticancer agent is an anticancer agent are alternative, epidermal growth factor receptor due to genetic drug resistance, epidermal growth factor receptor tyrosine kinase inhibitors is that. [Drawing] no (by machine translation)

A PROCESS FOR THE PREPARATION OF 4-FLUORO-2-METHOXY-5-NITROANILINE

The present invention is directed towards a process for the preparation of 4- fluoro-2-methoxy-5-nitroaniline (I) or salts thereof, wherein, 4-fluoro-2-methoxy aniline (III) is protected to obtain N-protected-(4-fiuoro-2-methoxy)aniline (VI), which is nitrated to obtain N-protected-(4-fluoro-2-methoxy-5-nitro)aniline (VII) and finally deprotected to obtain 4-fluoro-2-methoxy-5-nitroaniline (I) or salt thereof.

FUSED-RING OR TRICYCLIC ARYL PYRIMIDINE COMPOUND USED AS KINASE INHIBITOR

Disclosed is a fused-ring or tricyclic aryl pyrimidine compound used as a mutation selectivity EGFR inhibitor. Specifically, disclosed is a compound represented by formula (I) and used as an EGFR inhibitor or a pharmaceutically acceptable salt thereof.